AST-029

AST-029 is an early-stage drug candidate being developed by Astrogen, a South Korean biopharmaceutical company, for the treatment of Parkinson's Disease (PD). While the specific biological target and mechanism of action have not been publicly disclosed, Astrogen focuses on the development of small molecule therapies for neurological and neurodevelopmental disorders. The company has engaged in AI-driven drug discovery collaborations, such as with Iktos, to identify small molecule candidates for Parkinson's disease, although it is not explicitly confirmed if AST-029 originated from this specific partnership. The compound is currently in the early stages of development, transitioning from preclinical research toward clinical evaluation.